Staying on lazertinib with chemotherapy after the cancer grows again
Original title: Lazertinib plus pemetrexed and carboplatin in patients with EGFR-mutant advanced non-small cell lung cancer after progression on lazertinib.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This was tested in people, but only in a small middle stage trial with no comparison group.
The short version
People whose lung cancer grew on lazertinib did better when chemotherapy was added and the drug was kept going.
What was studied. A trial gave 86 people with advanced lung cancer lazertinib plus two chemotherapy drugs, pemetrexed and carboplatin. Everyone in the trial had cancer that grew while they were taking lazertinib before. About half, 46.5%, had a history of cancer that spread to the brain.
What they found. The cancer held steady for about 9.5 months, and people lived about 15.9 months. Tumors got smaller in 36.0% of people. In 36 people with brain spread seen on scans, the brain tumors held steady about 9.9 months.
What this means, and what it doesn't
What it could mean: If lazertinib stops working, staying on it and adding chemotherapy may help for a while. It also seemed to help hold back cancer in the brain. But side effects were common. Serious ones happened in 69.8% of people, mostly low blood counts.
What it doesn't mean: This was a middle stage trial with only one treatment group. There was no comparison group, so we cannot say the lazertinib part is what helped. The study team says bigger trials that compare groups are still needed. This is not a cure, and it is not standard care today. Also, this was lung cancer that had spread to the brain. It was not a study of tumors that start in the brain.
Source: PubMed, October 8, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.